Inactive Instrument

Pharmacyclics, Inc. Share Price

Stocks

End-of-day quote Nasdaq
- ^USD	-

07/15/07	Alexion Pharmaceuticals : to bolster rare disease offering with $8.4 billion deal	RE
29/15/29	Mylan NV : Exclusive - Perrigo expected to reject Mylan's latest offer	RE

07/15/07	Alexion Pharmaceuticals : to bolster rare disease offering with $8.4 billion deal	RE
29/15/29	Mylan NV : Exclusive - Perrigo expected to reject Mylan's latest offer	RE
22/15/22	Mylan NV : Generic drugmaker Teva makes $40 billion offer for rival Mylan	RE
22/15/22	Mylan NV : Exclusive - Perrigo expected to reject Mylan offer as soon as this week	RE
09/15/09	Actavis : Generic drugmaker Mylan offers $29 billion for Perrigo	RE
06/15/06	AbbVie : CEO defends Pharmacyclics deal to sceptical investors	RE
06/15/06	Wall Street closes up slightly ahead of jobs report	RE
05/15/05	AbbVie : CEO says new form of Humira could thwart generics	RE
05/15/05	AbbVie : boosts cancer drug pipeline with $21 billion Pharmacyclics deal	RE
05/15/05	AbbVie : Biotech buys get pharma M&A off to flying start in 2015	RE
05/15/05	AbbVie : boosts cancer drug pipeline with $21 billion Pharmacyclics deal	RE
02/14/02	Dai ichi Life Insurance : U.S. futures flat with Dow, S&P at record levels	RE

08/16/08	Pharmacyclics : Ibrutinib (IMBRUVICA®) Combination Data Show Promise in Patients with Relapsed/Refractory Multiple Myeloma	PU
08/16/08	Pharmacyclics : AbbVie’s Commitment to Oncology Demonstrated at the 57th American Society of Hematology Annual Meeting with 61 Abstracts Evaluating Medicines in Several Blood Cancers	PU
08/16/08	Pharmacyclics : IMBRUVICA® (ibrutinib) Awarded Prix Galien 2015 Best Pharmaceutical Agent	PU
08/16/08	Pharmacyclics : AbbVie Announces Submission of a Supplemental New Drug Application for IMBRUVICA® (ibrutinib) for Treatment–Naïve Chronic Lymphocytic Leukemia	PU
08/16/08	Pharmacyclics : IMBRUVICA® (ibrutinib) Now Approved to Treat Waldenström’s Macroglobulinemia in Europe	PU

06/15/06	Wall Street se reprend un peu dans un climat d'attente
06/15/06	DJ Industrial : Wall Street se reprend un peu dans un climat d'attente
05/15/05	AbbVie : Début d'année en fanfare pour les fusions dans la pharmacie
05/15/05	Début d'année en fanfare pour les fusions dans la pharmacie
05/15/05	AbbVie : Wall Street quasiment stable après les chiffres du chômage

Manager	Title	Age	Since
Scott Reents PRN	Corporate Officer/Principal	59	-
Dana Lee PRN	Corporate Officer/Principal	62	01/02/2013

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LONZA GROUP AG	-0.58%	+3.70%	+10.51%	+38.55%	4.89TCr
IQVIA HOLDINGS INC.	-0.73%	-0.41%	+48.84%	+36.72%	4.43TCr
REVOLUTION MEDICINES, INC.	+1.36%	+6.03%	+343.85%	+638.73%	4.38TCr
BEONE MEDICINES AG	-0.47%	-0.76%	+9.75%	+103.07%	4.15TCr
CELLTRION, INC.	+0.34%	+0.22%	+5.18%	+47.36%	3.01TCr
MEDPACE HOLDINGS, INC.	+1.00%	-1.28%	+24.23%	+156.93%	1.74TCr
EUROFINS SCIENTIFIC SE	-0.76%	-0.68%	+22.43%	+44.52%	1.5TCr
TEMPUS AI, INC.	-2.94%	+6.98%	+5.10%	-	1.49TCr
ASCENDIS PHARMA A/S	-0.86%	-4.00%	-	-	1.5TCr
Average	-0.40%	+0.61%	+58.74%	+152.27%	3.01TCr
Weighted average by Cap.	-0.22%	+1.21%	+74.80%	+168.50%

Employees

Sector